Boston Scientific halted the sales of its second-generation Watchman FLX in Europe because of higher-than-expected embolism rates. The complication resulted in one death that was linked to postoperative infection after the device was percutaneously removed.
Embolism Concerns Prompt Boston Scientific To Suspend Watchman FLX Sales In Europe
Tech Times - 6 Apr 2016 08:37
Boston Scientific halted the sales of its second-generation Watchman FLX in Europe because of higher-than-expected embolism rates. The complication resulted in one death that was linked to postoperative infection after the device was percutaneously removed.
Share this Article
Recommended